Endocrinology and Metabolism

Mi Yeon Kang (Kang MY)

5 Articles

Obesity and Metabolism
Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells: Mi Yeon Kang, Tae Jung Oh, Young Min Cho; Endocrinol Metab. 2015;30(2):216-220. Published online June 30, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.2.216

4,054 View
45 Download
42 Web of Science
41 Crossref

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that increases glucose-stimulated insulin secretion in pancreatic β-cells. Since mitochondrial function is crucial to insulin secretion, we hypothesized that GLP-1 may increase mitochondrial biogenesis in pancreatic β-cells. We treated INS-1 rat insulinoma cells with GLP-1 or exendin-4 for 48 hours and measured mitochondrial mass and function. Both GLP-1 and exendin-4 increased mitochondrial mass by approximately 20%. The mitochondria/cytosol ratio was increased from 7.60±3.12% to 10.53±2.70% by exendin-4. In addition, GLP-1 increased the mitochondrial membrane potential and oxygen consumption. Proliferator-activated receptor-gamma coactivator 1α expression was increased approximately 2-fold by GLP-1 treatment. In conclusion, the present study presents evidence for a new mechanism of action by which GLP-1 improves pancreatic β-cell function via enhanced mitochondrial mass and performance.

Citations

Citations to this article as recorded by

New fraternine analogues: Evaluation of the antiparkinsonian effect in the model of Parkinson's disease
Andréia Biolchi Mayer, Henrique de Oliveira Amaral, Danilo Gustavo R. de Oliveira, Gabriel Avohay Alves Campos, Priscilla Galante Ribeiro, Solange Cristina Rego Fernandes, Adolfo Carlos Barros de Souza, Raffael Júnio Araújo de Castro, Anamélia Lorenzetti
Neuropeptides.2024; 103: 102390. CrossRef
Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
Lidan Hu, Wenmin Wang, Xiangjun Chen, Guannan Bai, Liangjian Ma, Xin Yang, Qiang Shu, Xuekun Li
Brain‐X.2024;[Epub] CrossRef
Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice
Vicki Wang, Kuan-Yin Tseng, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Lun Lan, Zi-Rong Chen, Kuo-Hsing Ma, Nigel H. Greig, Jin Jung, Ho-II Choi, Lars Olson, Barry J. Hoffer, Yuan-Hao Chen
Journal of Biomedical Science.2024;[Epub] CrossRef
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Rae J. Herman, Heath D. Schmidt
Physiology & Behavior.2024; 281: 114565. CrossRef
Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro
Maija Vaittinen, Mariana Ilha, Elena Herbers, Anita Wagner, Kirsi A. Virtanen, Kirsi H. Pietiläinen, Eija Pirinen, Jussi Pihlajamäki
Diabetes Research and Clinical Practice.2023; 199: 110635. CrossRef
The cardioprotective effect of human glucagon‐like peptide‐1 receptor agonist (semaglutide) on cisplatin‐induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways
Marwa Mohamed Atef, Yasser Mostafa Hafez, Omnia Safwat El‐Deeb, Eman H. Basha, Radwa Ismail, Hanan Alshenawy, Rasha Osama El‐Esawy, Amira Kamel Eltokhy
Cell Biochemistry and Function.2023; 41(4): 450. CrossRef
Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
Yutong Zhou, Wendong Suo, Xinai Zhang, Jiaojiao Liang, Weizhe Zhao, Yue Wang, Hong Li, Qing Ni
Biomedicine & Pharmacotherapy.2023; 168: 115669. CrossRef
Soft X-ray tomography to map and quantify organelle interactions at the mesoscale
Valentina Loconte, Jitin Singla, Angdi Li, Jian-Hua Chen, Axel Ekman, Gerry McDermott, Andrej Sali, Mark Le Gros, Kate L. White, Carolyn A. Larabell
Structure.2022; 30(4): 510. CrossRef
Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
Belma Turan, Aysegul Durak, Yusuf Olgar, Erkan Tuncay
Molecular and Cellular Biochemistry.2022; 477(11): 2609. CrossRef
Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs
Carolin Thomas, Lia Wurzer, Ernst Malle, Michael Ristow, Corina T. Madreiter-Sokolowski
Frontiers in Aging.2022;[Epub] CrossRef
Anti-cancer effects of sitagliptin, vildagliptin, and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation
POOJA JAISWAL, VERSHA TRIPATHI, ANSHUL ASSAIYA, DHARMENDRA KASHYAP, RAHUL DUBEY, ANAMIKA SINGH, JANESH KUMAR, HEM CHANDRA JHA, RAJESH SHARMA, AMIT KUMAR DIXIT, HAMENDRA SINGH PARMAR
BIOCELL.2022; 46(12): 2645. CrossRef
Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats
Ilijana Babic, Dominic Sellers, Paul L Else, Jessica Nealon, Ashleigh L Osborne, Nagesh Pai, Katrina Weston-Green
Journal of Psychopharmacology.2021; 35(3): 284. CrossRef
Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease
Vicki Wang, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Yu-Ching Chou, Zhao-Yang Fu, Li-Wen Lai, Jin Jung, Hoi-II Choi, Doo-Sup Choi, Yazhou Li, Lars Olson, Nigel H. Greig, Barry J. Hoffer, Yuan-Hao Chen
ACS Pharmacology & Translational Science.2021; 4(2): 858. CrossRef
Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms
Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar, Marina Sokovi
Oxidative Medicine and Cellular Longevity.2021; 2021: 1. CrossRef
Vernicia fordii (Hemsl.) Airy Shaw extract stimulates insulin secretion in pancreatic β-cells and improves insulin sensitivity in diabetic mice
Jimin Hyun, Mi Hyeon Park, Yo Han Lee, Youngeun Lee, Su Ji Jeong, Sun Sil Choi, Keon Woo Khim, Hye Jin Eom, Jin-Hoe Hur, Chan Young Park, Jae-Ick Kim, Jiyoung Park, Hyung Won Ryu, Hyun-Jun Jang, Sei-Ryang Oh, Jang Hyun Choi
Journal of Ethnopharmacology.2021; 278: 114238. CrossRef
Connecting the dots between mitochondrial dysfunction and Parkinson’s disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity
Ishnoor Kaur, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Lotfi Aleya, Simona Bungau
Environmental Science and Pollution Research.2021; 28(28): 37060. CrossRef
Neuromodulatory effects of anti-diabetes medications: A mechanistic review
Habib Yaribeygi, Milad Ashrafizadeh, Neil C. Henney, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar
Pharmacological Research.2020; 152: 104611. CrossRef
Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
Shu-Yi Wang, Shey-Lin Wu, Ta-Cheng Chen, Chieh-Sen Chuang
International Journal of Environmental Research and Public Health.2020; 17(13): 4805. CrossRef
Visualizing subcellular rearrangements in intact β cells using soft x-ray tomography
Kate L. White, Jitin Singla, Valentina Loconte, Jian-Hua Chen, Axel Ekman, Liping Sun, Xianjun Zhang, John Paul Francis, Angdi Li, Wen Lin, Kaylee Tseng, Gerry McDermott, Frank Alber, Andrej Sali, Carolyn Larabell, Raymond C. Stevens
Science Advances.2020;[Epub] CrossRef
Nutrient Sensor mTOR and OGT: Orchestrators of Organelle Homeostasis in Pancreatic β-Cells
Nicholas Esch, Seokwon Jo, Mackenzie Moore, Emilyn U. Alejandro, Yingke Xu
Journal of Diabetes Research.2020; 2020: 1. CrossRef
Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1
Ana D. Martins, Mariana P. Monteiro, Branca M. Silva, Alberto Barros, Mário Sousa, Rui A. Carvalho, Pedro F. Oliveira, Marco G. Alves
Toxicology and Applied Pharmacology.2019; 362: 1. CrossRef
Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions
Hiroshi Watanabe, Yuki Enoki, Toru Maruyama
Biological and Pharmaceutical Bulletin.2019; 42(9): 1437. CrossRef
Recent Advances in Drug Repurposing for Parkinson’s Disease
Xin Chen, Giuseppe Gumina, Kristopher G. Virga
Current Medicinal Chemistry.2019; 26(28): 5340. CrossRef
Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function
Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
Journal of Cellular Physiology.2019; 234(6): 8402. CrossRef
Liraglutide protects against glucolipotoxicity‐induced RIN‐m5F β‐cell apoptosis through restoration of PDX1 expression
Edy Kornelius, Hsin‐Hua Li, Chiung‐Huei Peng, Yi‐Sun Yang, Wei‐Jen Chen, Yan‐Zin Chang, Yi‐Chiao Bai, Stanley Liu, Chien‐Ning Huang, Chih‐Li Lin
Journal of Cellular and Molecular Medicine.2019; 23(1): 619. CrossRef
The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts
Subhashis Pal, Shailendra K. Maurya, Sourav Chattopadhyay, Shyamsundar Pal China, Konica Porwal, Chirag Kulkarni, Sabyasachi Sanyal, Rohit A. Sinha, Naibedya Chattopadhyay
Biochemical Pharmacology.2019; 164: 34. CrossRef
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
Holly Green, Panagiota Tsitsi, Ioanna Markaki, Dag Aarsland, Per Svenningsson
CNS Drugs.2019; 33(2): 143. CrossRef
Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
Enrico Bagnoli, Una FitzGerald
European Journal of Neuroscience.2019; 49(4): 422. CrossRef
Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis
Chengcong Chen, Ying Huang, Yongmei Zeng, Xiyan Lu, Guoqing Dong
BMC Cardiovascular Disorders.2019;[Epub] CrossRef
Acute exposure to 3‑deoxyglucosone at high glucose levels impairs insulin secretion from β‑cells by downregulating the sweet taste receptor signaling pathway
Xiudao Song, Guoqiang Liang, Min Shi, Liang Zhou, Fei Wang, Lurong Zhang, Fei Huang, Guorong Jiang
Molecular Medicine Reports.2019;[Epub] CrossRef
Translational approaches to restoring mitochondrial function in Parkinson's disease
Heather Mortiboys, Ruby Macdonald, Thomas Payne, Matilde Sassani, Thomas Jenkins, Oliver Bandmann
FEBS Letters.2018; 592(5): 776. CrossRef
Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy
Eridan Rocha-Ferreira, Laura Poupon, Aura Zelco, Anna-Lena Leverin, Syam Nair, Andrea Jonsdotter, Ylva Carlsson, Claire Thornton, Henrik Hagberg, Ahad A Rahim
Brain.2018; 141(10): 2925. CrossRef
Current perspective of mitochondrial biology in Parkinson's disease
Navneet Ammal Kaidery, Bobby Thomas
Neurochemistry International.2018; 117: 91. CrossRef
Humanin promotes mitochondrial biogenesis in pancreatic MIN6 β-cells
Qingqing Qin, Jieqiong Jin, Fang He, Yongqin Zheng, Tingting Li, Yun Zhang, Jundong He
Biochemical and Biophysical Research Communications.2018; 497(1): 292. CrossRef
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson, Yazhou Li, Iciar Aviles-Olmos, Thomas T Warner, Patricia Limousin, Andrew J Lees, Nigel H Grei
The Lancet.2017; 390(10103): 1664. CrossRef
Alogliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits
Xiaowei Zhang, Zhiwei Zhang, Yungang Zhao, Ning Jiang, Jiuchun Qiu, Yajuan Yang, Jian Li, Xue Liang, Xinghua Wang, Gary Tse, Guangping Li, Tong Liu
Journal of the American Heart Association.2017;[Epub] CrossRef
Potential therapeutic interventions for chronic kidney disease‐associated sarcopenia via indoxyl sulfate‐induced mitochondrial dysfunction
Yuki Enoki, Hiroshi Watanabe, Riho Arake, Rui Fujimura, Kana Ishiodori, Tadashi Imafuku, Kento Nishida, Ryusei Sugimoto, Saori Nagao, Shigeyuki Miyamura, Yu Ishima, Motoko Tanaka, Kazutaka Matsushita, Hirotaka Komaba, Masafumi Fukagawa, Masaki Otagiri, To
Journal of Cachexia, Sarcopenia and Muscle.2017; 8(5): 735. CrossRef
The pancreas: Bandmaster of glucose homeostasis
Nathalie Jouvet, Jennifer L. Estall
Experimental Cell Research.2017; 360(1): 19. CrossRef
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Dilan Athauda, Thomas Foltynie
Drug Discovery Today.2016; 21(5): 802. CrossRef
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus
Long Jin, Sun Woo Lim, Jian Jin, Byung Ha Chung, Chul Woo Yang
Translational Research.2016; 174: 122. CrossRef
Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases
Tae Jung, Kyung Choi
International Journal of Molecular Sciences.2016; 17(2): 192. CrossRef

Discrepancy between the Growth Hormone and Insulin-like Growth Factor-I Concentrations in Patients with Acromegaly.: Ji Won Yoon, Mi Yeon Kang, Hwa Young Ahn, Jee Hyun An, Sang Wan Kim, Chan Soo Shin, Kyong Soo Park, Hak Chul Jang, Bo Youn Cho, Hong Kyu Lee, Seong Yeon Kim; J Korean Endocr Soc. 2008;23(6):395-403. Published online December 1, 2008; DOI: https://doi.org/10.3803/jkes.2008.23.6.395

1,875 View
25 Download

Abstract PDF: BACKGROUND
This study was performed to evaluate the frequency and clinical characteristics of patients with active acromegaly and who show discordance of the growth hormone (GH) level and the insulin-like growth factor-I (IGF-I) level. METHODS: We reviewed the medical records of the patients who were diagnosed with acromegaly between 01/01/1995 and 6/30/2007 at Seoul National University Hospital. We selected only the patients whose basal GH and IGF-I levels were available. We investigated the pre- and post-operative clinical characteristics, as well as the blood concentrations of GH and IGF-I. The concordance rate between the two hormones was examined. The patients were considered to have active disease on the basis of their IGF-I levels above the normal range, after adjustment for age and gender, and their mean basal GH value was > or = 2.5 microgram/L. The hormone levels and the clinical parameters were compared between the hormone concordant and discordant groups. RESULTS: We reviewed the preoperative records of 103 acromegalic patients, and these patients met the above-mentioned criteria. 53 postoperative patients who were not cured by operation were monitored without them receiving radiation or medical therapy. Both the basal GH and IGF-I levels were above normal in 103 patients preoperatively, and the discordant rate was 0% (0/103 cases). Postoperatively, the discordant rate between the two hormones was increased to 30.2% (16/53 cases). Age, gender, body mass index and tumor size were insignificantly different between the concordant and discordant groups. However, postoperative residual tumors were less frequently observed in the discordant group (P = 0.006). CONCLUSION: For the patients with acromegaly, unlike the 0% discordance preoperatively, 30.2% of patients showed a discrepancy between their GH and IGF-I levels postoperatively. The patients who had hormonal discrepancy were less likely to have residual tumors after operation. Considering the frequency of this hormonal discrepancy, both hormone levels should be measured to evaluate the disease activity after treatment. Further, oral glucose tolerance testing should be performed and especially for the patients with an increased GH level, but who have a normal IGF-I concentration.

The Clinical Implication and Problems of Adrenal Vein Sampling in Patients with Primary Aldosteronism.: Jie Seon Lee, Mi Yeon Kang, Sang Wan Kim, Chan Soo Shin, Seong Yeon Kim, Jin Wook Chung; J Korean Endocr Soc. 2007;22(6):428-435. Published online December 1, 2007; DOI: https://doi.org/10.3803/jkes.2007.22.6.428

2,210 View
21 Download
2 Crossref

Abstract PDF

BACKGROUND
Recently, the significance of primary aldosteronism is being recognized due to an increase in its incidence and its complications. However, it is difficult to differentiate primary aldosteronism based on radiological studies as the size of an aldosterone producing adenoma (APA) is small, and nonfunctioning adrenal incidentalomas are common. Adrenal vein sampling (AVS) has been considered as the gold standard for differentiating an aldosterone producing adenoma (APA) from bilateral idiopathic adrenal hyperplasia (BAH). The clinical implications and problems associated with AVS have not yet been reported in Korea. METHOD: Clinical data of 28 patients with primary aldosteronism who had undergone AVS in a hospital from 1995 to 2006 were retrospectively analyzed. RESULT: The study group comprised 13 males (46.4%) and 15 females (53.5%), with a mean age of 44.5 +/- 11.9 years. Clinical data indicated that 19 patients (67.9%) had APA and nine patients (32.1%) had BAH. AVS data demonstrated that 11 patients had APA and five patients had BAH. Two patients were not diagnosed despite successful AVS. AVS was not successful in 10 patients (37.5%); AV catheterization failed in two patients, was not selective in seven patients on the right side, and was not selective in one patient on the left side. CONCLUSION: AVS was helpful in primary aldosteronism patients with inconclusive CT and MRI findings. Selectivity of AVS should be appropriately assessed because of the technical problem of selective catheterization.

Citations

Citations to this article as recorded by

Bilateral Adrenocortical Masses Producing Aldosterone and Cortisol Independently
Seung-Eun Lee, Jae Hyeon Kim, You-Bin Lee, Hyeri Seok, In Seub Shin, Yeong Hee Eun, Jung-Han Kim, Young Lyun Oh
Endocrinology and Metabolism.2015; 30(4): 607. CrossRef
Primary Aldosteronism
Sang Wan Kim
Korean Journal of Medicine.2012; 82(4): 396. CrossRef

Retrospective Observation of Long-Term Clinical Courses of Idiopathic Central Diabetes Insipidus in Adults.: Hee Joung Kim, Mi Yeon Kang, Kyung Won Kim, Hyun Seung Jeong, Hae Sung Kim, Sang Wan Kim, Seong Yeon Kim; J Korean Endocr Soc. 2006;21(6):482-489. Published online December 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.6.482

1,732 View
17 Download
1 Crossref

Abstract PDF

BACKGROUND
Idiopathic central diabetes insipidus (CDI) can be diagnosed when it occurs in the absence of a genetic or secondary cause known to be responsible for diabetes insipidus (DI). Some studies have reported that idiopathic CDI in adults shows a more benign clinical course than in children and young patients. However, the clinical characteristics and progress of this disorder have not been fully described. Therefore, we investigated the clinical courses of adult patients over the age of sixteen years with idiopathic central DI. METHODS: We reviewed the medical records of all patients who had documented cases of idiopathic CDI from 1989 to 2005, and studied clinical features, hormone data, and imaging studies at diagnosis and during at least 1-year of follow-up. RESULTS: There were 9 male (30.0%) and 21 female (70.0%) patients with a mean age of 39.3 years at diagnosis and a mean follow-up duration of 6.9 years. At diagnosis, deficits in anterior pituitary hormones were documented in 6 patients (20%), hyperprolactinemia in 4, and hypogonadism in 2. Two patients had an anterior pituitary hormone deficiency that was newly detected at a mean 3.4 years after the onset of DI. On initial MRI, the posterior pituitary was not hyperintense in 7 of the 30 patients (23.3%), but pituitary stalk thickening was observed in 15 (50.0%). After a mean follow-up of 6.9 years (range: 1 to 18), follow-up pituitary MRI showed improvement or no changes in patients with initial MRI findings of a pituitary abnormality, and no development of new lesions in 7 patients with a normal pituitary finding on initial MRI. CONCLUSION: Two of the 30 patients with idiopathic CDI developed an anterior pituitary hormone deficiency during follow-up, but no subject showed any aggravation on follow-up MRI. No patient showed a newly developed pituitary abnormality on follow-up MRI after a negative finding on the initial MRI.

Citations

Citations to this article as recorded by

Central Diabetes Insipidus Surmised as from Post-obstructive Diuresis after Decompression Treatment for Neurogenic Bladder
Kang-Woo Lee, Chul-Woo Yang, Dong-Jun Lim, Hyuk-Sang Kwon, Mi-Ja Kang, Eun-Sook Kim, Kun-Ho Yoon, Ho-Young Son, Bong-Yun Cha
Journal of Korean Endocrine Society.2009; 24(2): 144. CrossRef

A Case of Adrenocortical Carcinoma showing Variable Cortisol Production during the Clinical Course.: Yun Hyi Ku, Hyung Jin Choi, Jin Taek Kim, Ji Won Yoon, Eun Kyung Lee, Hwa Young Cho, Mi Yeon Kang, Jie Seon Lee, Young Min Cho, Seong Yeon Kim; J Korean Endocr Soc. 2006;21(5):419-423. Published online October 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.5.419

1,516 View
21 Download

Abstract PDF: Patients with adrenocortical carcinoma (ACC) present with evidence of excessive adrenal steroid hormone in approximately 60% of cases, in which rapidly progressing Cushing's syndrome with or without virilization is the most frequent presentation. Some patients experience an increase or a decline in cortisol production through the progression of their ACC. We report on an unusual case of a cortisol-producing ACC, and the patient presented with a decline in cortisol production, followed by an increase in cortisol production, through the progression of the tumor. A 65-year-old woman who manifested with facial edema and weight gain was diagnosed with Cushing's syndrome, caused by cortisol producing ACC. The patient was treated with adrenalectomy. However, 8 months later, a metastatic hepatic tumor of recurred ACC was detected. At that time, the hormonal evaluation revealed that the liver mass did not produce any hormones. The patient was treated with metastatectomy. Four months later, a relapsed tumor was detected. Increased cortisol production was observed at that time. We speculate there was a change in the clonal dominance within the ACC and this change might cause such a difference. This is the first case report of ACC that showed variable hormone production during progression.

Author index